益心舒胶囊联合地高辛治疗慢性肺源性心脏病的临床研究

Clinical study on Yixinshu Capsules combined with digoxin in treatment of chronic pulmonary heart disease

目的探讨益心舒胶囊联合地高辛片治疗慢性肺源性心脏病的临床疗效。方法选取2015年6月-2018年6月南充市中心医院收治的80例慢性肺源性心脏病患者作为研究对象,采用随机数字表法将患者分为对照组和治疗组,每组各40例。对照组患者口服地高辛片,2片/次,1次/d;治疗组患者在对照组基础上口服益心舒胶囊,3粒/次,3次/d。两组患者均连续治疗4周。观察两组患者的临床疗效,比较两组治疗前后的心功能指标、肺功能指标、血气指标和心肌酶指标水平。结果治疗后,对照组和治疗组的总有效率分别为77.50%、95.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者左室舒张末内径(LVEED)、左室收缩末内径(LVESD)水平显著降低,左心射血分数(LVEF)水平显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组心功能指标显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者一秒用力呼气容积(FEV1)、用力肺活量(FVC)和FEV1/FVC水平显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组肺功能指标水平显著高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者动脉血pH值和二氧化碳分压(p CO2)水平显著降低,氧分压(p O2)水平显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血气指标水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者D-二聚体(D-D)、N末端B型钠尿肽原(NT-proBNP)和心肌肌钙蛋白I(CTnI)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组心肌酶指标水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论益心舒胶囊联合地高辛片治疗慢性肺源性心脏病具有较好的临床疗效,可改善患者心功能和肺功能,同时改善患者的血气指标和心肌酶指标,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Yixinshu Capsules combined with Digoxin Tablets in treatment of chronic pulmonary heart disease. Methods Patients(80 cases) with chronic pulmonary heart disease in Nanchong Central Hospital from June 2015 to June 2018 were divided into control and treatment groups by random number table method, and each group had 40 cases. Patients in the control group were po administered with Digoxin Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Yixinshu Capsules, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function indexes, lung function indexes, blood gas indexes, and serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.50% and 95.00%, respectively, and there were differences between two groups(P < 0.05). After treatment, LVEED and LVESD in the two groups were significantly decreased, but LVEF was significantly increased, and there were differences in the same group(P < 0.05). After treatment, the cardiac function indexes in the treatment group were significantly better than those in the control group, and there were differences between two groups(P < 0.05). After treatment, FEV1, FVC and FEV1/FVC in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, lung function indexes in the treatment group were higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, pH value and p CO2 levels in two groups were significantly decreased, but p O2 was significantly increased, and there were differences in the same group(P < 0.05). After treatment, blood gas indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, D-D, NT-proBNP, and CTnI levels in two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, serological indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Yixinshu Capsules combined with Digoxin Tablets has a good clinical effect in treatment of chronic pulmonary heart disease, and it can improve patients’ heart function and lung function, and improve the blood gas and myocardial enzyme indexes, which has a certain clinical application value.